Shire appoints Thomas Dittrich as CFO
Biopharmaceutical company Shire said on Monday that Thomas Dittrich will take up the role of chief financial officer early next year following a transition period from his current employer, Swiss engineering and manufacturing group Sulzer.
FTSE 100
8,109.32
16:35 18/11/24
FTSE 350
4,473.50
17:09 18/11/24
FTSE All-Share
4,431.13
16:49 18/11/24
Pharmaceuticals & Biotechnology
19,204.40
17:09 18/11/24
Shire Plc
4,690.00p
16:39 08/01/19
Dittrich is currently CFO at Sulzer, having joined the company in 2014, serving as chief executive officer ad interim between August 2017 and December 2015.
Prior to that, he worked served as vice president of finance corporate planning and chief accounting officer of Amgen Inc. between 2010 and 2014. Between 2006 and 2010, he was vice president of finance and chief financial officer of Amgen. He also spent eight years with Dell in various finance and general manager roles.
Shire's chief executive, Flemming Ornskov, said: "Thomas’s wealth of experience while leading the finance teams at numerous multinational companies, including Amgen for several years, will be a tremendous asset for Shire as we continue to execute as the leading global biotech focused on rare diseases.
"His unique financial skillset and results-oriented mentality make him the right person to lead Shire’s finance function."
At 1450 GMT, the shares were down 3% to 3,567p.